 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...8586878889909192939495...235236» |
- | methotrexate / Generic mfg.
Journal: Rescuing effect of folates on methotrexate cytotoxicity in human trophoblast cells. (Pubmed Central) - Jul 13, 2022
Despite the general acceptance of administering FA to prevent adverse events of MTX therapy, our findings suggest that FA may not be optimal, and indicate FTHF or MTHF as a better choice. This study on trophoblast cells suggests that FTHF may be the optimal folate, particularly for women in childbearing-age.
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Avastin (bevacizumab) / Roche
P2 data, Clinical Trial,Phase II, Journal: Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years. (Pubmed Central) - Jul 13, 2022
This study on trophoblast cells suggests that FTHF may be the optimal folate, particularly for women in childbearing-age. The efficacy of fluoropyrimidine plus bevacizumab was age-independent in patients with metastatic colorectal cancer aged ≥75 years, and attention should be paid to non-hematologic adverse events as age increases.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical data, Journal, Gene Expression Profile, PD(L)-1 Biomarker, IO biomarker: Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX. (Pubmed Central) - Jul 13, 2022
The efficacy of fluoropyrimidine plus bevacizumab was age-independent in patients with metastatic colorectal cancer aged ≥75 years, and attention should be paid to non-hematologic adverse events as age increases. Our results identify potential immune biomarkers for locally advanced pancreatic cancer and provide insights into pancreatic cancer immunity.
- || 5-fluorouracil / Generic mfg.
Clinical, Retrospective data, Review, Journal: Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials. (Pubmed Central) - Jul 13, 2022
This is the first meta-analysis of RCTs showing that NC improves OS for RPC compared with US followed by adjuvant therapy. Ongoing RCTs should confirm these findings with FOLFIRINOX to generalize the indication of NC.
- | albumin-bound paclitaxel / Generic mfg.
Journal: Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer. (Pubmed Central) - Jul 13, 2022
P=N/A
Chemosensitivity assay profiling is a promising tool for guiding therapy in advanced PDAC. Further prospective validation is under way (clinicaltrials.gov NCT03033927).
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Journal, HEOR, Patient reported outcomes: Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. (Pubmed Central) - Jul 13, 2022
P3
Further prospective validation is under way (clinicaltrials.gov NCT03033927). In addition to improving OS, encorafenib plus cetuximab with or without binimetinib delays QoL decline in previously treated patients with BRAF V600E-mutant mCRC.
- || Avastin (bevacizumab) / Roche
P2 data, Clinical Trial,Phase II, Journal, Circulating tumor DNA: Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11). (Pubmed Central) - Jul 13, 2022
Our biomarker study demonstrated no RAS mutations in ctDNA at disease progression in 62% of patients with RAS-mutant mCRC. Both OS and post-progression survival were better in patients with clearance of RAS mutations in ctDNA after triplet-based chemotherapy.
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Clinical, Journal, Real-world evidence: Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study. (Pubmed Central) - Jul 13, 2022
The incidence of grade 3-4 neutropenia and diarrhea was 23.3% and 2.7%, respectively. Our results support the use of nal-IRI+5-FU/LV in gemcitabine-refractory mPDAC and suggest that a lower starting dose followed by a re-escalation strategy could achieve clinical outcomes comparable to those with standard starting doses in real-world practice.
- | 5-fluorouracil / Generic mfg.
Journal, MRI: Induction Chemotherapy and Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy for Inoperable Pancreas Cancer. (Pubmed Central) - Jul 13, 2022
All received induction chemotherapy for a median 4.2 months (range, 0.2-13.3) most commonly FOLFIRINOX (n=43; 69.4%)...To our knowledge, this is the largest series of induction chemotherapy followed by ablative 5-fraction SMART delivered on an MR Linac for inoperable PDAC. The potential for this novel treatment strategy is to achieve long-term LC and OS, compared to chemotherapy alone, and warrants prospective evaluation.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Preclinical, Journal: Short duration treadmill exercise improves physical function and skeletal muscle mitochondria protein expression after recovery from FOLFOX chemotherapy in male mice. (Pubmed Central) - Jul 12, 2022
FOLFOX (5-FU, leucovorin, oxaliplatin) is a chemotherapy treatment for colorectal cancer which induces toxic side effects involving fatigue, weakness, and skeletal muscle dysfunction...Both exercise durations increased muscle VDAC and COXIV expression in FOLFOX mice. These data provide evidence that FOLFOX chemotherapy induces persistent deficits in physical function that can be partially reversed by short-duration aerobic exercise.
- || Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Opdivo (nivolumab) / BMS
Trial primary completion date: HCRN GI16-288: A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC (clinicaltrials.gov) - Jul 12, 2022
P2, N=78, Active, not recruiting, Sponsor: Patrick Boland
These data provide evidence that FOLFOX chemotherapy induces persistent deficits in physical function that can be partially reversed by short-duration aerobic exercise. Trial primary completion date: Jun 2022 --> Dec 2022
- | Bylantra (devimistat) / Cornerstone Pharma
Trial completion date, Combination therapy, Metastases: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jul 12, 2022
P1, N=21, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Jun 2022 --> Dec 2022 Trial completion date: Jun 2022 --> Dec 2022
- |||| Clinical: Dr. @pashtoonkasi weighed in on #research presented at #ASCO22 showing that the combination of FOLFIRI plus panitumumab may improve progression-free survival in patients with a subset of metastatic #ColonCancer. https://t.co/E0ZWKgywTW (Twitter) - Jul 11, 2022
- | Cyramza (ramucirumab) / Eli Lilly
Trial completion, Combination therapy: FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) (clinicaltrials.gov) - Jul 11, 2022
P2/3, N=180, Completed, Sponsor: Institut f
Trial completion date: Jun 2022 --> Dec 2022 Active, not recruiting --> Completed
- | Journal: ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy? (Pubmed Central) - Jul 9, 2022
Active, not recruiting --> Completed No abstract available
- | 5-fluorouracil / Generic mfg.
Journal: Impact of G-CSF Prophweylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma. (Pubmed Central) - Jul 8, 2022
Full DI was associated with a non-significant increase in PFS. These results need to be confirmed prospectively.
- | Retrospective data, Journal: Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study. (Pubmed Central) - Jul 8, 2022
These results need to be confirmed prospectively. Stratification according to prognostic score was useful in predicting the outcomes of UR-PC cases and may aid in identifying cases who might benefit from surgical treatment after responding to chemotherapy.
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study. (Pubmed Central) - Jul 8, 2022
The safety and feasibility of PIPAC-Ox + 5-FU/L appears to be similar to the safety and feasibility of PIPAC-Ox alone in patients with unresectable cPM. Oncological outcomes must be evaluated in larger studies.
- | Journal: Safety and Efficacy of Intraperitoneal Paclitaxel Plus Intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for Gastric Cancer with Peritoneal Metastasis. (Pubmed Central) - Jul 8, 2022
Oncological outcomes must be evaluated in larger studies. The biweekly regimen of IP paclitaxel and FOLFOX is safe and the recommended dose of IP paclitaxel for a phase II trial is 60 mg/m.
- | Tyvyt (sintilimab) / Eli Lilly, Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci, Avastin (bevacizumab) / Roche
Journal, Checkpoint inhibition, Tumor Mutational Burden, MSi-H Biomarker, IO biomarker: Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation. (Pubmed Central) - Jul 7, 2022
The four CRLM patients received toripalimab or sintilimab plus chemotherapy (FOLFOX or FOLFIRI or XELOX) with or without bevacizumab after POLE EDM were detected...Despite being a rare phenotype, CRLM patients with POLE EDM exhibit ultra-high TMB and, more importantly, significant clinical response to ICI-based combination therapy. Therefore, the complete sequencing of POLE exonuclease domains is recommended in CRLM patients clinically.
- | Fruzaqla (fruquintinib) / Takeda
New P2 trial, Metastases: Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 7, 2022
P2, N=134, Not yet recruiting, Sponsor: Weijian Guo
- ||| bemarituzumab (AMG 552) / Amgen
Trial completion, Metastases: FIGHT: A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (clinicaltrials.gov) - Jul 6, 2022
P2, N=155, Completed, Sponsor: Five Prime Therapeutics, Inc.
Therefore, the complete sequencing of POLE exonuclease domains is recommended in CRLM patients clinically. Active, not recruiting --> Completed
- | Trial completion date, Trial primary completion date: GRECCAR 15: Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer (clinicaltrials.gov) - Jul 6, 2022
P3, N=186, Recruiting, Sponsor: University Hospital, Bordeaux
Active, not recruiting --> Completed Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Jul 2022 --> Jul 2024
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Clinical, Journal: Plasma protein markers in advanced or metastatic colorectal cancer patients receiving chemotherapy with bevacizumab or cetuximab: Results from CALGB 80405 (Alliance). (Pubmed Central) - Jul 6, 2022
In this exploratory, hypothesis-generating analysis, the Angiome identified multiple prognostic biomarkers and two potential predictive biomarkers for mCRC patients enrolled in CALGB80405. PlGF and VEGF-D predicted lack of benefit from bevacizumab in a chemo-dependent manner.
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
P2 data, Journal: Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. (Pubmed Central) - Jul 6, 2022
P2
PlGF and VEGF-D predicted lack of benefit from bevacizumab in a chemo-dependent manner. The addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab is safe and improved progression-free survival in patients with previously untreated metastatic colorectal cancer.
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Retrospective data, Journal: Class III β-Tubulin Expression Is of Value in Selecting nab-Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer. (Pubmed Central) - Jul 6, 2022
The addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab is safe and improved progression-free survival in patients with previously untreated metastatic colorectal cancer. Class III β-tubulin might be a predictive factor for the response of GnP, but not a prognostic factor for OS, helping the selection of an optimized first-line chemotherapy regimen for unresectable PDAC.
- || Review, Journal: Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go? (Pubmed Central) - Jul 6, 2022
Controversies surrounding the role of NAT in PDAC treatment include applicability to different stages of PDAC, chemotherapy regimens, radiation, duration of treatment, and assessment of effect. This review aims to summarize the current progress and controversies of NAT in PDAC.
- || BMS-986371 / BMS
New P1 trial: A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine (clinicaltrials.gov) - Jul 5, 2022
P1, N=32, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | 5-fluorouracil / Generic mfg.
Journal: The survival impact of palliative chemotherapy dose modifications on metastatic colon cancer. (Pubmed Central) - Jul 5, 2022
This review aims to summarize the current progress and controversies of NAT in PDAC. Reduction in the dose intensity of palliative chemotherapy may adversely affect both disease progression and overall survival among mCC patients.
- | Trial completion date, Trial primary completion date, Combination therapy: Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Jul 5, 2022
P1, N=38, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Reduction in the dose intensity of palliative chemotherapy may adversely affect both disease progression and overall survival among mCC patients. Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma (clinicaltrials.gov) - Jul 5, 2022
P2, N=63, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023 Trial primary completion date: Jun 2022 --> Dec 2022
- | Biomarker, Trial completion date, Trial primary completion date: COBRA: Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery (clinicaltrials.gov) - Jul 5, 2022
P2/3, N=1408, Recruiting, Sponsor: NRG Oncology
Trial primary completion date: Jun 2022 --> Dec 2022 Trial completion date: Jul 2024 --> Apr 2027 | Trial primary completion date: Jul 2022 --> Apr 2025
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical: 65 y/o woman w/ mCRC, L sided, RAS WT, MSI-S, BRAF WT, HER 2 Neu +ve, s/p mFOLFOX+Pan and FOLFIRI + Bev, wt would u recommend as 3L in the community outside clinical trial? Is Ph2 data good enough? Sequencing? #GISM #OncTwitter @pashtoonkasi @marklewismd @GillSharlene @myESMO (Twitter) - Jul 3, 2022
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
RNF43m go with antiBRAF/ EGFRi first than FOLFIRINOX Bev? @skopetz (Twitter) - Jul 2, 2022
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Thank you @manjuggm! We did not specifically compare FOLFOX vs CAPOX but found no significant diff in type of chemo regimen given btw groups & no significant diff in percentage of chemo given either. (Twitter) - Jul 1, 2022
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Very interesting! Same for FOLFOX & CAPOX? Are younger patients getting more of one versus the other? Curious why the difference? Thank you! #WCGI2022 (Twitter) - Jul 1, 2022
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Journal: Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin. (Pubmed Central) - Jul 1, 2022
Trial completion date: Jul 2024 --> Apr 2027 | Trial primary completion date: Jul 2022 --> Apr 2025 Previous conventional irinotecan treatment does not compromise the efficacy of subsequent nal-IRI+5-FU/LV treatment in mPDAC patients.
- | levoleucovorin calcium / Generic mfg., leucovorin calcium / Generic mfg.
Preclinical, Journal: Absorption and Tissue Distribution of Folate Forms in Rats: Indications for Specific Folate Form Supplementation during Pregnancy. (Pubmed Central) - Jul 1, 2022
However, only 50% of the leucovorin is metabolically active whereas levofolinate is fully active and generates higher tetrahydrofolate (THF). Because levofolinate can readily incorporate into the folate cycle without needing methylenetetrahydrofolate reductase (MTHFR) and methionine synthase (MS) in the first pass and is relatively stable, it should be the folate form of choice during pregnancy, other disorders where large daily doses of folate are needed, and food fortification.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Two Cases of Robot-Assisted Total Pelvic Exenteration and Intracorporeal Ileal Conduit forLocally Advanced Rectal Cancer (Pubmed Central) - Jul 1, 2022
He was started on bevacizumab+S-1/oxaliplatin therapy in July 2019...In April 2019, he was started on FOLFOXIRI+cetuximab therapy...At present, ie, at postoperative 12 months, the patient remains free of recurrence and metastasis, with a CEA level of 7.3 ng/ml and CA19-9 level of 12 U/ml. Ra-TPE, which allows transperineal removal of a specimen, can be performed as a minimally invasive surgery in combination with ICIC.
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., cisplatin / Generic mfg.
Journal: PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. (Pubmed Central) - Jul 1, 2022
In contrast, the outcome of cisplatin-based chemotherapy (together with capecitabine or 5-fluorouracil) failed to be improved by concomitant treatment with pembrolizumab...This is a non sequitur. Based on the available clinical data, such approvals should be restricted to the use of oxaliplatin.
- | Retrospective data, Journal: Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer. (Pubmed Central) - Jun 30, 2022
In this cohort study that sought to evaluate the role of adaptive dynamic therapy in localized pancreatic cancer, selecting a chemotherapeutic regimen based on response to preoperative therapy was associated with improved survival. These findings support an individualized and in vivo assessment of response to perioperative therapy in pancreatic cancer.
- || 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
RAS遺伝子野生型の切除不能進行 #大腸がん で原発巣が右側患者においては #ベバシズマブ と #mFOLFOX6 の併用の方が良い可能性が報告されました。 #WCGIC22 https://t.co/k9MlnnuGOn (Twitter) - Jun 30, 2022
- || Opdivo (nivolumab) / BMS
Trial primary completion date: Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) (clinicaltrials.gov) - Jun 30, 2022
P2, N=74, Recruiting, Sponsor: Weill Medical College of Cornell University
These findings support an individualized and in vivo assessment of response to perioperative therapy in pancreatic cancer. Trial primary completion date: Feb 2026 --> Jan 2024
- | Retrospective data, Journal: Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. (Pubmed Central) - Jun 29, 2022
P3
The efficacy of anti-EGFR agents among RAS/BRAF wild-type patients unexposed to anti-EGFRs is higher than other options. The reintroduction of chemotherapy remains frequent in clinical practice.
- | 5-fluorouracil / Generic mfg.
Journal: The association of abdominal adiposity with premature discontinuation of postoperative chemotherapy in colon cancer. (Pubmed Central) - Jun 29, 2022
The reintroduction of chemotherapy remains frequent in clinical practice. Among patients with stage II-III colon cancer who initiate postoperative chemotherapy, excess visceral and intramuscular adiposity may be risk factors for the premature discontinuation of chemotherapy.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Efficacy, Safety, and Impact on Patient Survival of PDL1/PD-1 Inhibitors versus FOLFIRINOX Regimens for Advanced Pancreatic Cancer. (Pubmed Central) - Jun 29, 2022
The progression-free survival in the observation group was significantly higher than that in the comparison group, and there was a statistically significant difference between the two groups (P < 0.05). PDL1/PD-1 inhibitors in combination with FOLFIRINOX regimens have shown longer survival than treatment with FOLFIRINOX regimens for pancreatic cancer patients, with reliable clinical efficacy, tolerable adverse effects, and a high safety profile for patients.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A. (Pubmed Central) - Jun 29, 2022
NSC49L does not affect global protein synthesis. These studies provide a mechanistic understanding of NSC49L as a PP2A agonist, and how its combination with TRAIL sensitizes FOLFOX-resistant CRC cells.
- | numidargistat (INCB001158) / Calithera
Trial completion date, Combination therapy, Metastases: A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors (clinicaltrials.gov) - Jun 29, 2022
P1/2, N=149, Active, not recruiting, Sponsor: Incyte Corporation
These studies provide a mechanistic understanding of NSC49L as a PP2A agonist, and how its combination with TRAIL sensitizes FOLFOX-resistant CRC cells. Trial completion date: Jun 2022 --> Dec 2022
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Clinical Trial,Phase III, Journal, Combination therapy: The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab (Pubmed Central) - Jun 28, 2022
Cetuximab in combination with chemotherapy is a standard first-line treatment regimen for patients with metastatic colorectal cancer (mCRC) RAS wild-type (wt); however, the efficacy of cetuximab plus leucovorin, fluorouracil and oxaliplatin (FOLFOX) had never been demonstrated in a prospective, randomized, controlled phase III study. The TAILOR study is the first randomized, multicenter, prospective Phase III study evaluating the addition of cetuximab to FOLFOX in a RAS wt Chinese population and thus providing confirmatory data for the efficacy and safety of cetuximab plus FOLFOX versus FOLFOX alone.
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date: CheckMate 649: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (clinicaltrials.gov) - Jun 28, 2022
P3, N=2031, Active, not recruiting, Sponsor: Bristol-Myers Squibb
The TAILOR study is the first randomized, multicenter, prospective Phase III study evaluating the addition of cetuximab to FOLFOX in a RAS wt Chinese population and thus providing confirmatory data for the efficacy and safety of cetuximab plus FOLFOX versus FOLFOX alone. Trial completion date: Oct 2022 --> May 2024